About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Apoe
apolipoprotein E
MGI:88057
298 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Ay/a
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl
abnormal glomerular mesangium morphology J:177084
abnormal inflammatory response J:177084
abnormal kidney morphology J:177084
atherosclerotic lesions J:177084
decreased circulating adiponectin level J:177084
glomerulosclerosis J:177084
hyperglycemia J:177084
increased circulating cholesterol level J:177084
increased circulating insulin level J:177084
increased circulating leptin level J:177084
increased circulating triglyceride level J:177084
increased monocyte cell number J:177084
insulin resistance J:177084
obese J:177084
Ay/a
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl
decreased circulating adiponectin level J:177084
normal homeostasis/metabolism phenotype J:177084
increased circulating cholesterol level J:177084
increased circulating leptin level J:177084
Abca1tm1Jdm/Abca1tm1Jdm
Abcg1tm1Dgen/Abcg1tm1Dgen
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * DBA * DBA/1LacJ
abnormal hematopoietic system physiology J:190966
Albq4A/J/Albq4A/J
Apoetm1Unc/Apoetm1Unc
involves: A/J * C57BL/6J
albuminuria J:135073
Albq4A/J/Albq4C57BL/6J
Apoetm1Unc/Apoetm1Unc
involves: A/J * C57BL/6J
albuminuria J:135073
Angptl3tm1Lex/Angptl3tm1Lex
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6
decreased circulating cholesterol level J:149912
decreased circulating triglyceride level J:149912
Apoa2tm1Bres/Apoa2+
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * 129S4/SvJae
decreased circulating cholesterol level J:37250
Apoa2tm1Bres/Apoa2tm1Bres
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * 129S4/SvJae
decreased circulating cholesterol level J:37250
decreased circulating HDL cholesterol level J:37250
Apobtm1Sgy/Apobtm1Sgy
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
increased body weight J:41510
increased circulating cholesterol level J:41510
increased circulating triglyceride level J:41510
increased circulating VLDL cholesterol level J:41510
increased susceptibility to atherosclerosis J:41510
Apobtm2Sgy/Apobtm2Sgy
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
abnormal cholesterol homeostasis J:41510
decreased body weight J:41510
decreased circulating cholesterol level J:41510
decreased susceptibility to atherosclerosis J:41510
increased circulating HDL cholesterol level J:41510
increased circulating triglyceride level J:41510
increased circulating VLDL cholesterol level J:41510
increased circulating VLDL triglyceride level J:41510
Apobtm2Sgy/Apobtm2Sgy
Apoetm1Unc/Apoetm1Unc
Lepob/Lepob
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
abnormal circulating cholesterol level J:133453
atherosclerotic lesions J:133453
decreased circulating HDL cholesterol level J:133453
hyperglycemia J:133453
hypertension J:133453
impaired glucose tolerance J:133453
increased circulating cholesterol level J:133453
increased circulating free fatty acids level J:133453
increased circulating insulin level J:133453
increased circulating triglyceride level J:133453
increased circulating VLDL cholesterol level J:133453
obese J:133453
Apobec1tm1Chan/Apobec1tm1Chan
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S4/SvJae
abnormal circulating cholesterol level J:48202
decreased circulating cholesterol level J:48202
increased circulating cholesterol level J:48202
increased circulating triglyceride level J:48202
Apobec1tm1Ishi/Apobec1tm1Ishi
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
decreased cholesterol level J:41982
increased circulating triglyceride level J:41982
Apobec1tm1Rub/Apobec1tm1Rub
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
involves: 129P2/OlaHsd * C57BL/6
decreased circulating cholesterol level J:79196
decreased circulating LDL cholesterol level J:79196
increased circulating HDL cholesterol level J:79196
increased circulating triglyceride level J:79196
increased circulating VLDL triglyceride level J:79196
Apoc1tm2Lmh/Apoc1tm2Lmh
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6
abnormal cholesterol homeostasis J:28261
increased circulating cholesterol level J:28261
ApoeTg(rtTA)1Gaga/ApoeTg(rtTA)1Gaga
Igs7tm1(tetO-Apoe)Gaga/0
involves: 129S1/Sv * C57BL/6J
increased circulating cholesterol level J:136987
increased susceptibility to atherosclerosis J:136987
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
involves: 129P2/OlaHsd * C57BL/6
abnormal Bruch membrane morphology J:101147
abnormal lipid homeostasis J:48565, J:67282
abnormal lipid level J:48565, J:67282
abnormal retinal pigment epithelium morphology J:101147
atherosclerotic lesions J:48565
hyperlipidemia J:48565
increased circulating cholesterol level J:48565, J:67282
increased circulating triglyceride level J:48565, J:67282
increased susceptibility to atherosclerosis J:48565
normal liver/biliary system phenotype J:48565
retinal degeneration J:101147
xanthoma J:48565
Apoetm1(APOE*2)Mae/Apoetm1(APOE*2)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
abnormal lipid homeostasis J:67282
decreased susceptibility to hyperlipidemia J:67282
Apoetm1(APOE_i4)Sfu/Apoetm1(APOE_i4)Sfu
involves: 129P2/OlaHsd
abnormal circulating cholesterol level J:104859
abnormal plasma membrane morphology J:103515
abnormal response to CNS ischemic injury J:104859
Apoetm1(APOE_i4)Sfu/Apoetm1(APOE_i4)Sfu
involves: 129P2/OlaHsd * C57BL/6N
abnormal brain morphology J:60590
abnormal phospholipid level J:60590
decreased brain cholesterol level J:60590
increased circulating cholesterol level J:60590
increased circulating LDL cholesterol level J:60590
increased circulating VLDL cholesterol level J:60590
Apoetm1(APOE_i4)Sfu/Apoetm1(APOE_i4)Sfu
Tg(APPSWE)2576Kha/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL
normal homeostasis/metabolism phenotype J:121533
Apoetm1Bres/Apoetm1Bres
Bcl2tm1Irt/Bcl2tm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
atherosclerotic lesions J:144243
normal cardiovascular system phenotype J:144243
normal homeostasis/metabolism phenotype J:144243
increased macrophage apoptosis J:144243
Apoetm1Bres/Apoetm1Bres
C6Q0/C6Q0
involves: 129P2/OlaHsd
decreased susceptibility to atherosclerosis J:158457
Apoetm1Bres/Apoetm1Bres
Cd59atm1Bpm/Cd59atm1Bpm
involves: 129 * 129P2/OlaHsd
increased susceptibility to atherosclerosis J:158457
vascular smooth muscle hyperplasia J:158457
vascular smooth muscle hypoplasia J:158457
Apoetm1Bres/Apoetm1Bres
Cx3cr1tm1Ifc/Cx3cr1tm1Ifc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
decreased susceptibility to atherosclerosis J:81822
impaired macrophage chemotaxis J:81822
Apoetm1Bres/Apoetm1Bres
Esr1tm1Ksk/Esr1tm1Ksk
B6.129P2-Apoetm1Bres Esr1tm1Ksk
abnormal circulating cholesterol level J:68574
atherosclerotic lesions J:68574
normal homeostasis/metabolism phenotype J:68574
increased susceptibility to atherosclerosis J:68574
uterus atrophy J:68574
Apoetm1Bres/Apoetm1Bres
Fn1tm1Bwg/Fn1tm1Bwg
involves: 129S4/SvJae * C57BL/6
abnormal cholesterol homeostasis J:90917
decreased circulating VLDL cholesterol level J:90917
decreased susceptibility to atherosclerosis J:90917
Apoetm1Bres/Apoetm1Bres
Ifngr1tm1Agt/Ifngr1tm1Agt
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
abnormal apolipoprotein level J:40921
decreased susceptibility to atherosclerosis J:40921
increased circulating cholesterol level J:40921
increased circulating phospholipid level J:40921
Apoetm1Bres/Apoetm1Bres
Ltb4r1tm1Adl/Ltb4r1tm1Adl
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
decreased susceptibility to atherosclerosis J:117166
Apoetm1Bres/Apoetm1Bres
Mapk8tm1Flv/Mapk8tm1Flv
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
atherosclerotic lesions J:94044
Apoetm1Bres/Apoetm1Bres
Mapk9tm1Flv/Mapk9tm1Flv
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
abnormal macrophage morphology J:94044
abnormal macrophage physiology J:94044
decreased susceptibility to atherosclerosis J:94044
increased macrophage derived foam cell number J:94044
Apoetm1Bres/Apoetm1Bres
Plautm1Mlg/Plautm1Mlg
involves: 129 * C57BL/6
aortic elastic tissue lesions J:44387
decreased susceptibility to atherosclerosis J:44387
Apoetm1Bres/Apoetm1Bres
Plgtm1Jld/Plgtm1Jld
involves: 129P2/OlaHsd * C57BL/6 * NIH Black Swiss
abnormal body weight J:42927
atherosclerotic lesions J:42927
decreased circulating HDL cholesterol level J:42927
premature death J:42927
Apoetm1Khw/Apoetm1Khw
Tg(Mx1-cre)29-4Her/0
B6.Cg-Apoetm1Khw Tg(Mx1-cre)29-4Her
abnormal apolipoprotein level J:196923
abnormal circulating lipid level J:196923
hyperlipidemia J:196923
normal immune system phenotype J:196923
increased circulating cholesterol level J:196923
increased circulating VLDL cholesterol level J:196923
increased susceptibility to atherosclerosis J:196923
Apoetm1Khw/Apoetm1Khw
Tg(Mx1-cre)29-4Her/?
involves: 129S4/SvJae * C57BL/6 * SJL
increased circulating cholesterol level J:75681
increased circulating LDL cholesterol level J:75681
increased circulating triglyceride level J:75681
increased circulating VLDL cholesterol level J:75681
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
involves: 129S7/SvEvBrd * C57BL/6
normal homeostasis/metabolism phenotype J:117317
increased circulating cholesterol level J:117317
increased circulating HDL cholesterol level J:117317
increased circulating LDL cholesterol level J:117317
increased circulating triglyceride level J:117317
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
atherosclerotic lesions J:129557
increased susceptibility to atherosclerosis J:129557
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Tg(Mx1-cre)29-4Her/0
involves: 129S7/SvEvBrd * C57BL/6J * SJL
abnormal circulating enzyme level J:90547
abnormal circulating protein level J:90547
decreased circulating cholesterol level J:90547
decreased circulating LDL cholesterol level J:90547
decreased circulating triglyceride level J:90547
decreased circulating VLDL cholesterol level J:90547
increased circulating cholesterol level J:117317
increased circulating factor VIII level J:90547, J:117317
increased circulating HDL cholesterol level J:117317
increased circulating LDL cholesterol level J:117317
increased circulating triglyceride level J:117317
increased circulating von Willebrand factor level J:90547
increased susceptibility to atherosclerosis J:90547
Apoetm1Rraf/Apoetm1Rraf
Tg(Mx1-cre)29-4Her/0
B6.Cg-Apoetm1Rraf Tg(Mx1-cre)29-4Her
abnormal apolipoprotein level J:196923
abnormal circulating cholesterol level J:196923
decreased circulating VLDL cholesterol level J:196923
decreased susceptibility to atherosclerosis J:196923
hyperlipidemia J:196923
normal immune system phenotype J:196923
increased circulating cholesterol level J:196923
Apoetm1Unc/Apoe+
Tg(APPV717I)1130Kha/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
premature death J:43446
Apoetm1Unc/Apoe+
Cyp4f13Gt(OST14770)Lex/Cyp4f13Gt(OST14770)Lex
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6
decreased susceptibility to atherosclerosis J:289999
Apoetm1Unc/Apoetm1Unc
Arhgef26tm1.1Kbur/Arhgef26tm1.1Kbur
B6.Cg-Arhgef26tm1.1Kbur Apoetm1Unc
decreased susceptibility to atherosclerosis J:195919
Apoetm1Unc/Apoetm1Unc
Ath29C57BL/6J/?
involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6J
increased susceptibility to atherosclerosis J:127711
Apoetm1Unc/Apoetm1Unc
Ath29C57BL/6J/Ath29C57BL/6J
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath30C57BL/6J/Ath30C57BL/6J
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath31C57BL/6J/Ath31C57BL/6J
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath32C57BL/6J/Ath32C57BL/6J
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Ath33C3H/HeJ/Ath33C3H/HeJ
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Athsq3C3H/HeJ/Athsq3C3H/HeJ
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Athsq3C57BL/6J/Athsq3C57BL/6J
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Cath1C3H/HeJ/Cath1C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased susceptibility to atherosclerosis J:129301
Apoetm1Unc/Apoetm1Unc
Cath1C57BL/6J/Cath1C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased susceptibility to atherosclerosis J:129301
Apoetm1Unc/Apoetm1Unc
Cav1tm1Mls/Cav1tm1Mls
involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * SJL
decreased susceptibility to atherosclerosis J:101788
increased circulating cholesterol level J:101788
increased circulating LDL cholesterol level J:101788
increased circulating triglyceride level J:101788
increased circulating VLDL cholesterol level J:101788
Apoetm1Unc/Apoetm1Unc
Cbstm1Unc/Cbstm1Unc
Tg(Mt1-CBS)25Waku/0
involves: 129P2/OlaHsd * C3H * C57BL/6
decreased body weight J:168131
increased circulating homocysteine level J:168131
increased circulating methionine level J:168131
increased circulating tumor necrosis factor level J:168131
increased Ly6C high monocyte number J:168131
increased monocyte cell number J:168131
increased susceptibility to atherosclerosis J:168131
Apoetm1Unc/Apoetm1Unc
Ccr1tm1Gao/Ccr1tm1Gao
involves: 129P2/OlaHsd * 129S4/SvJae
atherosclerotic lesions J:128063
increased interferon-gamma secretion J:128063
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
decreased susceptibility to atherosclerosis J:111471
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2tm1Ifc
B6.Cg-Apoetm1Unc Ccr2tm1Ifc
decreased monocyte cell number J:153310
decreased susceptibility to atherosclerosis J:153310
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
decreased susceptibility to atherosclerosis J:111471
impaired macrophage chemotaxis J:111471
Apoetm1Unc/Apoetm1Unc
Ccr2tm1Ifc/Ccr2tm1Ifc
Cx3cl1tm1Lira/Cx3cl1tm1Lira
B6.Cg-Apoetm1Unc Cx3cl1tm1Lira Ccr2tm1Ifc
decreased monocyte cell number J:153310
decreased susceptibility to atherosclerosis J:153310
Apoetm1Unc/Apoetm1Unc
Ccr5tm1Blck/Ccr5tm1Blck
involves: 129P2/OlaHsd * C57BL/6
abnormal cytokine secretion J:128063
abnormal lymphocyte physiology J:128063
abnormal mononuclear phagocyte morphology J:128063
atherosclerotic lesions J:128063
decreased interferon-gamma secretion J:128063
decreased T cell number J:128063
increased interleukin-10 secretion J:128063
Apoetm1Unc/Apoetm1Unc
Ccr5tm1Kuz/Ccr5tm1Kuz
involves: 129P2/OlaHsd * C57BL/6
abnormal cytokine secretion J:128063
abnormal lymphocyte physiology J:128063
abnormal mononuclear phagocyte morphology J:128063
abnormal vascular smooth muscle morphology J:128063
atherosclerotic lesions J:128063
decreased interferon-gamma secretion J:128063
decreased T cell number J:128063
increased interleukin-10 secretion J:128063
Apoetm1Unc/Apoetm1Unc
Cd36tm1Mfe/Cd36tm1Mfe
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
abnormal lipid level J:61672
abnormal macrophage derived foam cell morphology J:61672
abnormal macrophage physiology J:61672
decreased circulating triglyceride level J:61672
decreased susceptibility to atherosclerosis J:61672
increased cholesterol level J:61672
increased growth rate J:61672
xanthoma J:61672
Apoetm1Unc/Apoetm1Unc
Cd44tm1Mak/Cd44+
B6.129P2-Cd44tm1Mak Apoetm1Unc
decreased susceptibility to atherosclerosis J:72315
Apoetm1Unc/Apoetm1Unc
Cd44tm1Mak/Cd44tm1Mak
B6.129P2-Cd44tm1Mak Apoetm1Unc
decreased susceptibility to atherosclerosis J:72315
Apoetm1Unc/Apoetm1Unc
Cdh18Tg(GFAP-APOE_i4)1Hol/0
B6.Cg-Apoetm1Unc Cdh18Tg(GFAP-APOE_i4)1Hol/J
abnormal astrocyte physiology J:58019
Apoetm1Unc/Apoetm1Unc
Cdkn1atm1Tyj/Cdkn1atm1Tyj
B6.129-Apoetm1Unc Cdkn1atm1Tyj
abnormal response/metabolism to endogenous compounds J:125247
abnormal vascular smooth muscle physiology J:125247
decreased sensitivity to induced morbidity/mortality J:125247
decreased susceptibility to atherosclerosis J:125247
delayed cellular replicative senescence J:125247
Apoetm1Unc/Apoetm1Unc
Clutm1Jakh/Clutm1Jakh
Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
involves: 129P2/OlaHsd * 129S2/SvPas
amyloid beta deposits J:107702
amyloidosis J:107702
Apoetm1Unc/Apoetm1Unc
Crptm1Hjf/Crptm1Hjf
B6.Cg-Crptm1Hjf Apoetm1Unc
decreased circulating HDL cholesterol level J:170409
decreased circulating triglyceride level J:170409
increased circulating HDL cholesterol level J:170409
increased susceptibility to atherosclerosis J:170409
Apoetm1Unc/Apoetm1Unc
Csf1op/Csf1op
involves: 129P2/OlaHsd * C3HeB/Fe * C57BL/6
decreased susceptibility to atherosclerosis J:40136
increased circulating cholesterol level J:40136
Apoetm1Unc/Apoetm1Unc
Cst3tm1Karl/Cst3tm1Karl
involves: 129S/SvEv * C57BL/6
abnormal aorta elastic tissue morphology J:106879
abnormal aorta tunica media morphology J:106879
abnormal aortic arch morphology J:106879
abnormal enzyme/coenzyme activity J:106879
abnormal enzyme/coenzyme level J:106879
atherosclerotic lesions J:106879
vascular smooth muscle hyperplasia J:106879
Apoetm1Unc/Apoetm1Unc
Cx3cl1tm1Sgs/Cx3cl1tm1Sgs
B6.129-Apoetm1Unc Cx3cl1tm1Sgs
decreased susceptibility to atherosclerosis J:95279
impaired macrophage chemotaxis J:95279
increased macrophage derived foam cell number J:95279
Apoetm1Unc/Apoetm1Unc
Cx3cr1tm1Zm/Cx3cr1+
B6.129-Apoetm1Unc Cx3cr1tm1Zm
decreased susceptibility to atherosclerosis J:103047
Apoetm1Unc/Apoetm1Unc
Cx3cr1tm1Zm/Cx3cr1tm1Zm
B6.129-Apoetm1Unc Cx3cr1tm1Zm
decreased susceptibility to atherosclerosis J:103047
Apoetm1Unc/Apoetm1Unc
Cxcl10tm1Adl/Cxcl10tm1Adl
B6.129-Cxcl10tm1Adl Apoetm1Unc
abdominal aorta aneurysm J:166204
abnormal aorta morphology J:166204
abnormal CD4-positive, alpha beta T cell number J:166204
abnormal macrophage chemotaxis J:166204
aorta dilation J:166204
aortic aneurysm J:166204
decreased susceptibility to atherosclerosis J:166204
hematoma J:166204
increased sensitivity to induced morbidity/mortality J:166204
thoracic aorta aneurysm J:166204
Apoetm1Unc/Apoetm1Unc
Cyp4f13Gt(OST14770)Lex/Cyp4f13Gt(OST14770)Lex
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6
abnormal macrophage chemotaxis J:289999
decreased cholesterol level J:289999
decreased susceptibility to atherosclerosis J:289999
increased cholesterol efflux J:289999
Apoetm1Unc/Apoetm1Unc
Cyp19a1tm1Esi/Cyp19a1tm1Esi
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
abnormal aorta bulb morphology J:184647
abnormal gonadal fat pad morphology J:184647
abnormal liver morphology J:184647
atherosclerotic lesions J:184647
decreased circulating HDL cholesterol level J:184647
decreased circulating insulin level J:184647
hypertension J:184647
impaired glucose tolerance J:184647
increased body weight J:184647
increased circulating C-reactive protein level J:184647
increased circulating cholesterol level J:184647
increased circulating glucose level J:184647
increased circulating interleukin-6 level J:184647
increased circulating LDL cholesterol level J:184647
increased circulating triglyceride level J:184647
increased circulating tumor necrosis factor level J:184647
increased circulating VLDL cholesterol level J:184647
increased fat cell size J:184647
increased liver weight J:184647
increased systemic arterial blood pressure J:184647
insulin resistance J:184647
microvesicular hepatic steatosis J:184647
Apoetm1Unc/Apoetm1Unc
Ddit3tm1.1Irt/Ddit3tm1.1Irt
Taglntm2(cre)Yec/Tagln+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
decreased susceptibility to atherosclerosis J:233223
normal homeostasis/metabolism phenotype J:233223
Apoetm1Unc/Apoetm1Unc
Dp(17Nfkbil1-Olfr91)1Cogr/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
decreased susceptibility to atherosclerosis J:190754
normal homeostasis/metabolism phenotype J:190754
Apoetm1Unc/Apoetm1Unc
Egr1tm1Jmi/Egr1tm1Jmi
involves: 129 * C57BL/6
abnormal susceptibility to atherosclerosis J:96665
Apoetm1Unc/Apoetm1Unc
Fabp4tm1Brsp/Fabp4tm1Brsp
Fabp5tm1Hota/Fabp5tm1Hota
B6.Cg-Fabp4tm1Brsp Fabp5tm1Hota Apoetm1Unc
decreased body weight J:102223
decreased circulating cholesterol level J:102223
decreased circulating glucose level J:102223
decreased circulating triglyceride level J:102223
decreased susceptibility to atherosclerosis J:102223
improved glucose tolerance J:102223
increased insulin sensitivity J:102223
normal mortality/aging J:102223
Apoetm1Unc/Apoetm1Unc
Faslpr/Faslpr
B6.Cg-Apoetm1Unc Faslpr
abnormal aorta morphology J:121671
abnormal femur morphology J:121671
abnormal heart morphology J:121671
abnormal trabecular bone morphology J:121671
abnormal vascular endothelial cell morphology J:121671
abnormal vertebrae morphology J:121671
atherosclerotic lesions J:121671
decreased autoantibody level J:121671
decreased bone mineral density J:121671
decreased bone trabecula number J:121671
decreased CD4-positive, alpha beta T cell number J:121671
decreased CD8-positive, alpha-beta T cell number J:121671
decreased circulating cholesterol level J:121671
decreased trabecular bone connectivity density J:121671
decreased trabecular bone thickness J:121671
decreased trabecular bone volume J:121671
enlarged lymph nodes J:121671
enlarged spleen J:121671
enlarged thymus J:121671
glomerulonephritis J:121671
normal hematopoietic system phenotype J:121671
increased anti-double stranded DNA antibody level J:121671
increased autoantibody level J:121671
increased IgG level J:121671
increased kidney apoptosis J:121671
increased renal glomerulus lobularity J:121671
increased renal tubule apoptosis J:121671
increased urine protein level J:121671
renal glomerular immunoglobulin deposits J:121671
renal glomerulus hypertrophy J:121671
Apoetm1Unc/Apoetm1Unc
Faslpr/Faslpr
MRL.Cg-Apoetm1Unc Faslpr
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased circulating cholesterol level J:133606
increased immunoglobulin level J:133606
increased susceptibility to atherosclerosis J:133606
increased susceptibility to systemic lupus erythematosus J:133606
Apoetm1Unc/Apoetm1Unc
Faslgld/Faslgld
B6.Cg-Faslgld Apoetm1Unc
abnormal lymph node morphology J:91058
abnormal renal glomerulus morphology J:91058, J:200141
atherosclerotic lesions J:91058, J:200141
blood vessel inflammation J:91058
decreased circulating HDL cholesterol level J:91058
enlarged lymph nodes J:91058, J:200141
enlarged spleen J:91058
impaired macrophage phagocytosis J:91058
increased anti-nuclear antigen antibody level J:91058, J:200141
increased apoptosis J:91058
increased autoantibody level J:91058
increased circulating cholesterol level J:91058, J:200141
increased circulating LDL cholesterol level J:91058
increased circulating triglyceride level J:91058
increased circulating VLDL cholesterol level J:91058
increased IgG level J:91058
increased spleen weight J:91058, J:200141
increased susceptibility to atherosclerosis J:91058
increased T cell number J:91058
increased urine protein level J:91058
kidney inflammation J:200141
Apoetm1Unc/Apoetm1Unc
Fut4tm1Jbl/Fut4tm1Jbl
Fut7tm1Jbl/Fut7tm1Jbl
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
atherosclerotic lesions J:102212
Apoetm1Unc/Apoetm1Unc
Gja5tm1Mchn/Gja5tm1Mchn
Tg(TIE2-lacZ)182Sato/0
involves: 129P2/OlaHsd * BALB/c * C57BL/6
abnormal neutrophil physiology J:162224
alveolitis J:162224
normal cardiovascular system phenotype J:162224
increased susceptibility to atherosclerosis J:162224
Apoetm1Unc/Apoetm1Unc
Glg1Gt(RST092)Byg/Glg1+
B6J.129P2-Apoetm1Unc Glg1Gt(RST092)Byg
atherosclerotic lesions J:226586
normal cardiovascular system phenotype J:226586
decreased macrophage cell number J:226586
impaired macrophage chemotaxis J:226586
increased collagen level J:226586
Apoetm1Unc/Apoetm1Unc
Gofm1C57BL/6J/?
involves: C3H/HeJ * C57BL/6J
abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm2C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J
abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm2C57BL/6J/?
involves: C3H/HeJ * C57BL/6J
abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm3C57BL/6J/?
involves: C3H/HeJ * C57BL/6J
abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Gofm4C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J
abnormal gonadal fat pad morphology J:115779
Apoetm1Unc/Apoetm1Unc
Hdl5C57BL/6J/Hdl5C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq19C57BL/6J/Hdlq19C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased circulating HDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq86C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J
increased circulating HDL cholesterol level J:129301
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq86C3H/HeJ/Hdlq86C3H/HeJ
involves: C3H/HeJ * C57BL/6J
increased circulating HDL cholesterol level J:129301
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Hdlq91C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J
increased circulating HDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Hhipl1tm1a(KOMP)Wtsi/Hhipl1tm1a(KOMP)Wtsi
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N
decreased susceptibility to atherosclerosis J:280707
Apoetm1Unc/Apoetm1Unc
Hptm1Alev/Hptm1Alev
involves: 129
abnormal macrophage chemotaxis J:134942
atherosclerotic lesions J:134942
Apoetm1Unc/Apoetm1Unc
Hsd11b1tm1Lex/Hsd11b1tm1Lex
B6.129-Hsd11b1tm1Lex Apoetm1Unc
abnormal bone marrow cell physiology J:199430
abnormal cytokine secretion J:199430
abnormal macrophage derived foam cell morphology J:199430
normal behavior/neurological phenotype J:199430
normal cardiovascular system phenotype J:199430
decreased cholesterol level J:199430
decreased macrophage cell number J:199430
decreased susceptibility to atherosclerosis J:199430
decreased tumor necrosis factor secretion J:199430
normal growth/size/body region phenotype J:199430
hyperlipidemia J:199430
normal immune system phenotype J:199430
Apoetm1Unc/Apoetm1Unc
Ifngtm1Ts/Ifngtm1Ts
B6.129-Apoetm1Unc Ifngtm1Ts
abdominal aorta aneurysm J:166204
aorta dilation J:166204
increased body weight J:166204
increased sensitivity to induced morbidity/mortality J:166204
Apoetm1Unc/Apoetm1Unc
Il1r1tm1Imx/Il1r1tm1Imx
B6.129-Il1r1tm1Imx Apoetm1Unc
abnormal blood vessel physiology J:148173
decreased circulating interleukin-6 level J:148173
decreased susceptibility to atherosclerosis J:148173
decreased systemic arterial blood pressure J:148173
increased vasoconstriction J:148173
increased vasodilation J:148173
Apoetm1Unc/Apoetm1Unc
Il1rntm1Dih/Il1rntm1Dih
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6
abnormal aorta elastic tissue morphology J:132570
abnormal coronary artery morphology J:132570
abnormal macrophage chemotaxis J:132570
normal cardiovascular system phenotype J:132570
decreased body weight J:132570
decreased circulating cholesterol level J:132570
premature death J:132570
Apoetm1Unc/Apoetm1Unc
Il10tm1Cgn/Il10tm1Cgn
involves: 129P2/OlaHsd * C57BL/6
abnormal arterial thrombosis J:105858
abnormal blood coagulation J:105858
abnormal circulating cholesterol level J:105858
abnormal circulating cytokine level J:105858
decreased circulating VLDL cholesterol level J:105858
increased circulating interferon-gamma level J:105858
increased circulating interleukin-12 level J:105858
increased circulating LDL cholesterol level J:105858
increased susceptibility to atherosclerosis J:105858
Apoetm1Unc/Apoetm1Unc
Itgb3tm1Hyn/Itgb3tm1Hyn
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
anemia J:83615
atherosclerotic lesions J:83615
decreased susceptibility to diet-induced obesity J:83615
increased sensitivity to induced morbidity/mortality J:83615
lung inflammation J:83615
postnatal lethality, incomplete penetrance J:83615
premature death J:83615
Apoetm1Unc/Apoetm1Unc
Klf15tm1Jain/Klf15tm1Jain
involves: 129P2/OlaHsd * 129X1/SvJ
increased circulating cholesterol level J:203920
increased circulating triglyceride level J:203920
increased sensitivity to induced morbidity/mortality J:203920
increased susceptibility to atherosclerosis J:203920
Apoetm1Unc/Apoetm1Unc
Klf15tm2Jain/Klf15tm2Jain
Tg(Tagln-cre)1Jjl/0
involves: 129P2/OlaHsd * FVB/N
blood vessel inflammation J:203920
normal homeostasis/metabolism phenotype J:203920
increased macrophage cell number J:203920
increased susceptibility to atherosclerosis J:203920
vascular smooth muscle hypoplasia J:203920
Apoetm1Unc/Apoetm1Unc
Lcattm1Hgc/Lcattm1Hgc
involves: 129P2/OlaHsd * C57BL/6 * DBA
abnormal cholesterol homeostasis J:75567
abnormal circulating protein level J:75567
abnormal lipid homeostasis J:75567
normal homeostasis/metabolism phenotype J:75567
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd
increased circulating cholesterol level J:59491
Apoetm1Unc/Apoetm1Unc
Ldlrtm1Her/Ldlrtm1Her
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
abnormal impulse conducting system conduction J:95598
abnormal response to cardiac infarction J:95598
abnormal ST segment J:95598
abnormal synapse morphology J:43043
abnormal thrombosis J:95598
atherosclerotic lesions J:95598
decreased circulating troponin level J:95598
decreased myocardial infarction size J:95598
Apoetm1Unc/Apoetm1Unc
Leprdb/Leprdb
involves: 129P2/OlaHsd * C57BLKS/J
abnormal retina morphology J:103714
abnormal retinal vasculature morphology J:103714
Apoetm1Unc/Apoetm1Unc
Lgals3tm1Poi/Lgals3tm1Poi
involves: 129/Sv * C57BL/6 * SJL
decreased susceptibility to atherosclerosis J:130923
increased circulating cholesterol level J:130923
Apoetm1Unc/Apoetm1Unc
Lipgtm1Tq/Lipgtm1Tq
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
atherosclerotic lesions J:93987
decreased susceptibility to atherosclerosis J:93987
increased circulating cholesterol level J:93987
increased circulating HDL cholesterol level J:93987
increased circulating LDL cholesterol level J:93987
increased circulating phospholipid level J:93987
increased circulating triglyceride level J:93987
increased circulating VLDL cholesterol level J:93987
Apoetm1Unc/Apoetm1Unc
Lpltm1Sem/Lpltm1Sem
involves: 129P2/OlaHsd
abnormal circulating cholesterol level J:151434
abnormal circulating lipid level J:151434
abnormal vascular wound healing J:151434
hyperlipidemia J:151434
increased circulating cholesterol level J:151434
increased circulating triglyceride level J:151434
increased susceptibility to induced thrombosis J:151434
Apoetm1Unc/Apoetm1Unc
Mmp9tm1Tvu/Mmp9tm1Tvu
involves: 129P2/OlaHsd * 129S6/SvEvTac
decreased macrophage cell number J:110044
decreased susceptibility to atherosclerosis J:110044
vascular smooth muscle hypoplasia J:110044
Apoetm1Unc/Apoetm1Unc
Msr1tm1Csk/Msr1tm1Csk
either: (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J * ICR) or (involves: 129P2/OlaHsd * 129X1/SvJ * 129/Sv * ICR)
atherosclerotic lesions J:39079
increased circulating cholesterol level J:39079
Apoetm1Unc/Apoetm1Unc
Nceh1tm1Ishi/Nceh1tm1Ishi
B6.129-Nceh1tm1Ishi Apoetm1Unc
abnormal cholesterol homeostasis J:152385
increased susceptibility to atherosclerosis J:152385
Apoetm1Unc/Apoetm1Unc
Ncf1tm1Shl/Ncf1tm1Shl
involves: 129P2/OlaHsd * 129S2/SvPas
abnormal descending thoracic aorta morphology J:123854
abnormal susceptibility to atherosclerosis J:154332
aortic aneurysm J:123854
decreased acute inflammation J:123854
decreased systemic arterial systolic blood pressure J:123854
Apoetm1Unc/Apoetm1Unc
Nfe2l2tm1Mym/Nfe2l2tm1Mym
involves: 129P2/OlaHsd * C57BL/6J
abnormal aorta morphology J:143903
abnormal macrophage physiology J:143903
decreased susceptibility to atherosclerosis J:143903
increased circulating glucose level J:143903
increased circulating triglyceride level J:143903
oxidative stress J:143903
Apoetm1Unc/Apoetm1Unc
Nhdlq11C3H/HeJ/Nhdlq11C3H/HeJ
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Nhdlq11C3H/HeJ/Nhdlq11C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Nhdlq12C3H/HeJ/Nhdlq12C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Nhdlq12C57BL/6J/Nhdlq12C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
atherosclerotic lesions J:64566
decreased cholesterol level J:64566
normal homeostasis/metabolism phenotype J:64566
increased body weight J:64566
Apoetm1Unc/Apoetm1Unc
Nos3tm1Plh/Nos3tm1Plh
B6.129-Nos3tm1Plh Apoetm1Unc
aortic aneurysm J:103306
aortic dissection J:103306
cardiac fibrosis J:103306
decreased cardiac muscle contractility J:103306
dilated heart left ventricle J:103306
increased mean systemic arterial blood pressure J:103306
increased susceptibility to atherosclerosis J:103306
thick interventricular septum J:103306
thick ventricular wall J:103306
Apoetm1Unc/Apoetm1Unc
Nos3tm1Unc/Nos3tm1Unc
B6.129P2-Nos3tm1Unc Apoetm1Unc
abnormal cardiovascular system morphology J:60670
abnormal renal glomerulus morphology J:60670
aortic sinus aneurysm J:60670
atherosclerotic lesions J:60670
decreased kidney weight J:60670
increased circulating creatinine level J:60670
increased susceptibility to atherosclerosis J:60670
increased systemic arterial systolic blood pressure J:60670
Apoetm1Unc/Apoetm1Unc
Npc1m1N/Npc1m1N
involves: 129P2/OlaHsd * BALB/c
increased circulating VLDL cholesterol level J:104996
Apoetm1Unc/Apoetm1Unc
Pecam1Gt(OST16303)Lex/Pecam1Gt(OST16303)Lex
B6.129-Apoetm1Unc Pecam1Gt(OST16303)Lex
abnormal aorta endothelium morphology J:142083
atherosclerotic lesions J:142083
normal homeostasis/metabolism phenotype J:142083
Apoetm1Unc/Apoetm1Unc
Pik3cgtm1Dwu/Pik3cgtm1Dwu
B6.Cg-Apoetm1Unc Pik3cgtm1Dwu
atherosclerotic lesions J:121582
decreased circulating cholesterol level J:121582
Apoetm1Unc/Apoetm1Unc
Pla2g15tm1Ytan/Pla2g15tm1Ytan
involves: 129S/SvEv * B6.129P2-Apoetm1Unc/J
abnormal macrophage morphology J:97471
atherosclerotic lesions J:97471
increased circulating cholesterol level J:97471
Apoetm1Unc/Apoetm1Unc
Pnhdlc1C57BL/6J/Pnhdlc1C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Pnhdlc6C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J
increased circulating LDL cholesterol level J:129301
increased circulating VLDL cholesterol level J:129301
Apoetm1Unc/Apoetm1Unc
Pon1tm1Lus/Pon1tm1Lus
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J
atherosclerotic lesions J:82696
oxidative stress J:82696
Apoetm1Unc/Apoetm1Unc
Ptgdrtm1Dgen/Ptgdrtm1Dgen
involves: 129P2/OlaHsd * C57BL/6
increased cholesterol level J:192168
increased circulating cholesterol level J:192168
increased circulating triglyceride level J:192168
Apoetm1Unc/Apoetm1Unc
Rag2tm1Fwa/Rag2+
involves: 129P2/OlaHsd * 129S/SvEv
abnormal aorta morphology J:59156
decreased body weight J:59156
decreased circulating cholesterol level J:59156
decreased circulating HDL cholesterol level J:59156
increased uterus weight J:59156
Apoetm1Unc/Apoetm1Unc
Rag2tm1Fwa/Rag2tm1Fwa
involves: 129P2/OlaHsd * 129S/SvEv
abnormal aorta morphology J:59156
decreased body weight J:59156
decreased circulating cholesterol level J:59156
decreased circulating HDL cholesterol level J:59156
increased uterus weight J:59156
Apoetm1Unc/Apoetm1Unc
Scarb1tm1Kri/Scarb1tm1Kri
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6
abnormal coronary artery morphology J:201999
abnormal heart morphology J:201999
artery occlusion J:201999
atherosclerotic lesions J:201999
increased heart weight J:201999
premature death J:201999
Apoetm1Unc/Apoetm1Unc
Scarb1tm1Kri/Scarb1tm1Kri
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
abnormal erythrocyte morphology J:75090
decreased hematocrit J:75090
decreased hemoglobin content J:75090
echinocytosis J:75090
hypochromic macrocytic anemia J:75090
macrocytosis J:75090
poikilocytosis J:75090
reticulocytosis J:75090
Apoetm1Unc/Apoetm1Unc
Serpind1tm1Moto/Serpind1+
involves: 129P2/OlaHsd * C57BL/6 * CBA
abnormal urine nucleoside level J:122173
atherosclerotic lesions J:122173
oxidative stress J:122173
Apoetm1Unc/Apoetm1Unc
Serpine1tm1Mlg/Serpine1tm1Mlg
B6.129-Serpine1tm1Mlg Apoetm1Unc
atherosclerotic lesions J:61287
increased circulating cholesterol level J:61287
Apoetm1Unc/Apoetm1Unc
Smarcd1tm1.1Jddl/Smarcd1tm1.1Jddl
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA
abnormal bile salt homeostasis J:228944
decreased circulating cholesterol level J:228944
decreased susceptibility to atherosclerosis J:228944
Apoetm1Unc/Apoetm1Unc
Soat1tm1Far/Soat1tm1Far
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J
abnormal brain morphology J:61147
abnormal cholesterol homeostasis J:61147
abnormal cholesterol level J:61147
abnormal coat appearance J:61147
abnormal dermal layer morphology J:61147
abnormal skin condition J:61147
abnormal skin morphology J:61147
atherosclerotic lesions J:61147
decreased circulating cholesterol level J:61147
decreased circulating VLDL cholesterol level J:61147
hyperkeratosis J:61147
skin fibrosis J:61147
skin inflammation J:61147
skin lesions J:61147
sparse hair J:61147
thick dermal layer J:61147
xanthoma J:61147
Apoetm1Unc/Apoetm1Unc
Soat2tm1Far/Soat2tm1Far
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J
decreased circulating cholesterol level J:81836
decreased susceptibility to atherosclerosis J:81836
increased circulating HDL cholesterol level J:81836
increased circulating triglyceride level J:81836
increased phosphatidylcholine-sterol O-acyltransferase activity J:81836
Apoetm1Unc/Apoetm1Unc
Spp1tm1Blh/Spp1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J
atherosclerotic lesions J:86531
Apoetm1Unc/Apoetm1Unc
Spp1tm1Blh/Spp1tm1Blh
involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J
abnormal macrophage physiology J:86531
aortic aneurysm J:86531
atherosclerotic lesions J:86531
Apoetm1Unc/Apoetm1Unc
Spp1tm1Rit/Spp1+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
decreased susceptibility to atherosclerosis J:103051
increased circulating cholesterol level J:103051
increased circulating triglyceride level J:103051
Apoetm1Unc/Apoetm1Unc
Spp1tm1Rit/Spp1tm1Rit
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
calcified artery J:103051
decreased susceptibility to atherosclerosis J:103051
increased circulating cholesterol level J:103051
increased circulating triglyceride level J:103051
Apoetm1Unc/Apoetm1Unc
Sprr3tm1.1Ppy/Sprr3tm1.1Ppy
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J * SJL
abnormal vascular smooth muscle physiology J:230470
normal cardiovascular system phenotype J:230470
increased cellular sensitivity to hydrogen peroxide J:230470
increased susceptibility to atherosclerosis J:230470
vascular smooth muscle hypoplasia J:230470
Apoetm1Unc/Apoetm1Unc
Tg(APOC1)1Bres/0
involves: 129P2/OlaHsd * C57BL/6J * CBA/J
atherosclerotic lesions J:80689
hyperlipidemia J:80689
impaired lipolysis J:80689
increased circulating cholesterol level J:80689
increased circulating LDL cholesterol level J:80689
increased circulating triglyceride level J:80689
increased circulating VLDL cholesterol level J:80689
increased circulating VLDL triglyceride level J:80689
increased lipoprotein lipase activity J:80689
increased triglyceride lipase activity J:80689
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
involves: 129P2/OlaHsd * C57BL/6
amyloid beta deposits J:127846, J:133058
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/Tg(APPV717F)109Ili
involves: 129P2/OlaHsd
amyloid beta deposits J:107702
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
Tg(GFAP-APOE_i2)14Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
amyloid beta deposits J:127846
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
Tg(GFAP-APOE_i3)37Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
amyloid beta deposits J:127846, J:133058
Apoetm1Unc/Apoetm1Unc
Tg(APPV717F)109Ili/0
Tg(GFAP-APOE_i4)#Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
amyloid beta deposits J:127846, J:133058
Apoetm1Unc/Apoetm1Unc
Tg(APPV717I)1130Kha/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
premature death J:43446
Apoetm1Unc/Apoetm1Unc
Tg(CAG-IL1RN)1Cga/?
involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB
decreased circulating serum amyloid protein level J:132570
decreased susceptibility to atherosclerosis J:132570
Apoetm1Unc/Apoetm1Unc
Tg(CAG-IL1RN)2Cga/?
involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB
decreased circulating serum amyloid protein level J:132570
decreased susceptibility to atherosclerosis J:132570
Apoetm1Unc/Apoetm1Unc
Tg(CMV-Serpine1)1Dgi/0
B6.Cg-Apoetm1Unc Tg(CMV-Serpine1)1Dgi
atherosclerotic lesions J:61287
increased circulating cholesterol level J:61287
Apoetm1Unc/Apoetm1Unc
Tg(EIF1AX-Aldh2*E487K)101Oht/Tg(EIF1AX-Aldh2*E487K)101Oht
B6.Cg-Apoetm1Unc Tg(EIF1AX-Aldh2*E487K)101Oht
impaired spatial learning J:137374
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i3)1Rabr/0
involves: 129P2/OlaHsd * C57BL/6J * ICR
abnormal nervous system physiology J:55835, J:100975
abnormal spatial learning J:100975
normal behavior/neurological phenotype J:100975
enhanced coordination J:100975
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i3)1Rabr/0
involves: 129P2/OlaHsd * ICR
normal behavior/neurological phenotype J:101973
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i4)1Rabr/0
involves: 129P2/OlaHsd * C57BL/6J * ICR
abnormal spatial learning J:100975
normal behavior/neurological phenotype J:100975
decreased vertical activity J:100975
normal nervous system phenotype J:55835
neurodegeneration J:55835, J:100975
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APOE_i4)1Rabr/0
involves: 129P2/OlaHsd * ICR
abnormal dendrite morphology J:101973
increased anxiety-related response J:101973
increased startle reflex J:101973
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APP*751)10Cord/0
involves: 129P2/OlaHsd * C57BL/6
gliosis J:133156
increased cerebral infarction size J:133156
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APP*751)10Cord/0
Cdh18Tg(GFAP-APOE_i4)1Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
decreased cerebral infarction size J:133156
gliosis J:133156
Apoetm1Unc/Apoetm1Unc
Tg(Eno2-APP*751)10Cord/0
Tg(GFAP-APOE_i3)37Hol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
decreased cerebral infarction size J:133156
gliosis J:133156
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i3)37Hol/0
B6.Cg-Apoetm1Unc Tg(GFAP-APOE_i3)37Hol
abnormal fear/anxiety-related behavior J:71062
abnormal locomotor behavior J:71062
abnormal response to new environment J:71062
abnormal spatial learning J:71062
abnormal stationary movement J:71062
decreased startle reflex J:71062
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i3)37Hol/0
B6.Cg-Tg(GFAP-APOE_i3)37Hol Apoetm1Unc/J
abnormal astrocyte physiology J:58019
abnormal axon extension J:93487
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i4)22Hol/0
B6.Cg-Apoetm1Unc Tg(GFAP-APOE_i4)22Hol
abnormal axon extension J:93487
Apoetm1Unc/Apoetm1Unc
Tg(GFAP-APOE_i4)#Hol/0
B6.Cg-Apoetm1Unc Tg(GFAP-APOE_i4)#Hol
abnormal locomotor behavior J:71062
abnormal response to new environment J:71062
abnormal spatial learning J:71062
abnormal spatial working memory J:71062
abnormal stationary movement J:71062
decreased startle reflex J:71062
Apoetm1Unc/Apoetm1Unc
Tg(MSR1-Plau)1Ddi/0
involves: 129P2/OlaHsd * C57BL/6 * SJL
abnormal artery morphology J:102208
abnormal heart morphology J:101486
artery occlusion J:101486, J:102208
enlarged heart J:101486
heart inflammation J:101486
increased sensitivity to induced morbidity/mortality J:102208
increased susceptibility to atherosclerosis J:102208
Apoetm1Unc/Apoetm1Unc
Tg(NOS3)2Crom/0
involves: 129P2/OlaHsd * C57BL/6 * FVB
decreased circulating cholesterol level J:80701
decreased susceptibility to atherosclerosis J:80701
decreased systemic arterial blood pressure J:80701
Apoetm1Unc/Apoetm1Unc
Tg(NOS3)3Crom/0
involves: 129P2/OlaHsd * C57BL/6 * FVB
decreased circulating cholesterol level J:80701
decreased susceptibility to atherosclerosis J:80701
decreased systemic arterial blood pressure J:80701
Apoetm1Unc/Apoetm1Unc
Tg(Prnp-Abca1)EHol/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
amyloid beta deposits J:131400
Apoetm1Unc/Apoetm1Unc
Thbdtm1.1(THBD)Sltz/Thbdtm1.1(THBD)Sltz
B6.129(FVB)-Thbdtm1.1(THBD)Sltz Apoetm1Unc
abnormal enzyme/coenzyme activity J:191461
normal homeostasis/metabolism phenotype J:191461
Apoetm1Unc/Apoetm1Unc
Timp1tm1Pds/Y
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
abnormal blood vessel physiology J:103082
Apoetm1Unc/Apoetm1Unc
Tlr4tm1Aki/Tlr4tm1Aki
involves: 129P2/OlaHsd * C57BL/6
abnormal susceptibility to atherosclerosis J:91481
Apoetm1Unc/Apoetm1Unc
Tnfrsf11btm1Eac/Tnfrsf11btm1Eac
involves: 129S4/SvJaeSor * C57BL/6
abnormal aorta morphology J:128053
abnormal brachiocephalic trunk morphology J:128053
atherosclerotic lesions J:128053
Apoetm1Unc/Apoetm1Unc
Tnfsf4Ath1-C57BL/6J/Tnfsf4Ath1-C57BL/6J
involves: C3H/HeJ * C57BL/6J
atherosclerotic lesions J:140288
Apoetm1Unc/Apoetm1Unc
Trigq3C3H/HeJ/?
involves: C3H/HeJ * C57BL/6J
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Trigq3C3H/HeJ/Trigq3C3H/HeJ
involves: C3H/HeJ * C57BL/6J
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Trigq4C3H/HeJ/Trigq4C3H/HeJ
involves: C3H/HeJ * C57BL/6J
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Trigq4C3H/HeJ/Trigq4C57BL/6J
involves: C3H/HeJ * C57BL/6J
increased triglyceride level J:129301
Apoetm1Unc/Apoetm1Unc
Ttpatm1Far/Ttpa+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
abnormal vitamin E level J:66419
atherosclerotic lesions J:66419
Apoetm1Unc/Apoetm1Unc
Ttpatm1Far/Ttpatm1Far
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
abnormal lipid homeostasis J:66419
atherosclerotic lesions J:66419
Apoetm1Unc/Apoetm2(APOE_i3)Yhg
Zbtb20Tg(PDGFB-APPSwInd)20Lms/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2
amyloid beta deposits J:184138
Apoetm1Unc/Apoetm3(APOE_i4)Yhg
Zbtb20Tg(PDGFB-APPSwInd)20Lms/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2
amyloid beta deposits J:184138
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
B6.129P2-Apoetm2(APOE*3)Mae
hyperactivity J:139186
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
involves: 129P2/OlaHsd * C57BL/6
abnormal retinal pigment epithelium morphology J:101147
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
involves: 129P2/OlaHsd * C57BL/6J
abnormal lipid homeostasis J:41705
abnormal lipid level J:41705
abnormal triglyceride level J:41705
atherosclerotic lesions J:48565
decreased circulating LDL cholesterol level J:41705
decreased circulating VLDL cholesterol level J:74417
decreased circulating VLDL triglyceride level J:74417
decreased interleukin-6 secretion J:86768
decreased susceptibility to atherosclerosis J:74417
decreased tumor necrosis factor secretion J:86768
increased circulating cholesterol level J:41705
increased circulating HDL cholesterol level J:74417
increased circulating triglyceride level J:74417
increased susceptibility to atherosclerosis J:41705
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
abnormal circulating lipid level J:146721
amyloid beta deposits J:146721
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Tg(APPSWE)2576Kha/?
involves: 129P2/OlaHsd * C57BL/6 * SJL
amyloid beta deposits J:98636
Apoetm2(APOE*3)Mae/Apoetm2(APOE*3)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: 129P2/OlaHsd * C57BL/6
abnormal astrocyte morphology J:136318
abnormal microglial cell morphology J:136318
amyloid beta deposits J:136318
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
B6.129P2-Apoetm3(APOE*4)Mae
abnormal spatial reference memory J:97643
abnormal spatial working memory J:97643
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
involves: 129P2/OlaHsd * C57BL/6
abnormal Bruch membrane morphology J:101147
abnormal circulating lipid level J:151284
abnormal epididymal fat pad morphology J:151284
abnormal fat cell morphology J:151284
abnormal glucose homeostasis J:151284
abnormal lipid level J:74417
abnormal postnatal growth J:151284
abnormal response to infection J:138241
abnormal retinal pigment epithelium morphology J:101147
amyloid beta deposits J:101147
corneal opacity J:138241
decreased circulating HDL cholesterol level J:74417
decreased circulating triglyceride level J:74417
impaired glucose tolerance J:151284
increased circulating VLDL cholesterol level J:74417
increased circulating VLDL triglyceride level J:74417
increased interleukin-6 secretion J:86768
increased susceptibility to atherosclerosis J:74417
increased tumor necrosis factor secretion J:86768
retinal degeneration J:101147
retinal neovascularization J:101147
retinal pigment epithelium atrophy J:101147
thin retinal outer nuclear layer J:101147
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Ldlrtm1(LDLR)Mae/Ldlr+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
abnormal circulating lipid level J:146721
amyloid beta deposits J:146721
increased circulating cholesterol level J:146721
increased circulating triglyceride level J:146721
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Tg(APPSWE)2576Kha/?
involves: 129P2/OlaHsd * C57BL/6 * SJL
amyloid beta deposits J:98636
cerebral amyloid angiopathy J:98636
Apoetm3(APOE*4)Mae/Apoetm3(APOE*4)Mae
Tg(Thy1-APPSwDutIowa)BWevn/?
involves: 129P2/OlaHsd * C57BL/6
abnormal astrocyte morphology J:136318
abnormal microglial cell morphology J:136318
amyloid beta deposits J:136318
Apoetm3(APOE_i3)Sfu/Apoetm3(APOE_i3)Sfu
involves: 129P2/OlaHsd
abnormal response to CNS ischemic injury J:104859
decreased circulating cholesterol level J:104859
normal homeostasis/metabolism phenotype J:103515
Apoetm3(APOE_i3)Sfu/Apoetm3(APOE_i3)Sfu
Tg(APPSWE)2576Kha/0
involves: C57BL/6 * C57BL/6N * SJL
normal homeostasis/metabolism phenotype J:121533
Soat1tm1Ishi/Soat1tm1Ishi
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
abnormal dermal layer morphology J:63468
abnormal lipid homeostasis J:63468
abnormal skin condition J:63468
alopecia J:63468
decreased hair follicle number J:63468
dry eyes J:63468
increased circulating cholesterol level J:63468
Meibomian gland atrophy J:63468
mixed cellular infiltration to dermis J:63468
skin lesions J:63468
thick dermal layer J:63468
thick skin J:63468
xanthoma J:63468
Tg(APOE_i3*,APOC1)2Lmh/?
B6.Cg-Tg(APOE*3,APOC1)2Lmh
abnormal blood vessel elastic tissue morphology J:101995
atherosclerotic lesions J:101995
Tg(APOE_i3*,APOC1)2Lmh/?
involves: C57BL/6J * CBA
atherosclerotic lesions J:228420
increased circulating cholesterol level J:228420
increased circulating LDL cholesterol level J:228420
increased circulating triglyceride level J:228420
increased circulating VLDL cholesterol level J:228420
increased susceptibility to atherosclerosis J:228420
Tg(Gfap-APOE_i4)50Hube/Tg(Gfap-APOE_i4)50Hube
involves: C57BL/6 * DBA/2
abnormal locomotor activation J:100970
normal behavior/neurological phenotype J:100970
Tg(Gfap-APOE_i4*L28P)12Hube/Tg(Gfap-APOE_i4*L28P)12Hube
involves: C57BL/6 * DBA/2
normal behavior/neurological phenotype J:100970
Tg(Prnp-APOE4)3R1Dbo/?
involves: C3H/HeJ * C57BL/6J
normal nervous system phenotype J:72987

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/23/2021
MGI 6.16
The Jackson Laboratory